Champions Biotechnology sets up UK subsidiary

Champions Biotechnology, a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a UK subsidiary, Champions Biotechnology UK, to expand its personalized oncology business.

The company has appointed Guy Malchi as general manager of the UK subsidiary, which will also have a branch in Israel.

Mr Malchi previously served as CEO for Optimata, a development stage biopharmaceutical company focused on developing biosimulation technologies that predict cancer patients’ response to treatment. Prior to that, Mr Malchi was based in London with Tefen, a management consulting firm where he served as the founding partner of Tefen’s European life science practice.

Doug Burkett, president of Champions Biotechnology, said: Champions Biotechnology UK (CBUK) will enable our services to be accessible to many more physicians in Europe and beyond. The growing trend of medical tourism in Israel has prompted us to establish a branch in Israel to offer our services there as well.

I am delighted to welcome Guy Malchi on board as he transitions from consultant to take on the leadership role for CBUK. He will also lead our corporate development efforts, which are focused on in-licensing and co-development of oncology drug candidates that have proven successful in our Biomerk Tumorgraft platform. Guy’s expertise in strategy implementation and business development are a valuable benefit to Champions.